Navigation Links
NeoStem Named 'Best Stem Cell Company' in The New Economy's 2010 Biotech Awards
Date:7/6/2010

NEW YORK, July 6 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that it has been selected for the award "Best Stem Cell Company, 2010" in The New Economy's Biotech Awards, which identify excellence in the field of technology.

According to The New Economy's editor Jan Spiegel, who chaired the panel overseeing the awards, "Biotechnology is an exciting field, perhaps nowhere more so than in the area of adult stem cells. The building of NeoStem's adult stem cell platform and its leadership role in this field has been gaining increased recognition including from the Pontifical Council for Culture of the Vatican in the recently announced exclusive collaboration."

Robin Smith, NeoStem's Chairman and CEO, will accept the award at a presentation and interview to be held at the London Stock Exchange on Thursday, July 8, 2010 at 11:00 a.m. GMT. Dr. Smith commented, "We are very pleased to be recognized by The New Economy as an industry leader in stem cells. NeoStem's VSEL(TM) technology represents the cornerstone of our R&D efforts to advance stem cell treatments in two of the world's largest pharmaceutical markets, US and China."

About The New Economy

The New Economy captures the spirit of thought leadership. Both the magazine and the website are committed to the very highest standards of journalism, working together with experts from leading technology think tanks, public and private sector organizations, and academics from the most esteemed educational and research centers around the world, to bring regularly updated news, deep analysis of the issues of the day and clear and precise explanations of emerging technologies.

Winners of The New Economy 2010 Awards have been selected based on criteria such as innovation, originality and quality of product, as well as proof of market development and excellence in client representation.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSELTM Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include the future of VSEL TM Technology as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    For more information, please contact:

    NeoStem, Inc.
     Robin Smith, CEO
     Phone: +1-212-584-4174
     Email: rsmith@neostem.com
     Web:   http://www.neostem.com

    CCG Investor Relations, Inc.
     Kalle Ahl, Account Manager
     Phone: +1-646-833-3417
     Email: kalle.ahl@ccgir.com
     Web:   http://www.ccgirasia.com

     Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem Achieves New Milestone as Company Joins Russell 3000 Index
2. NeoStem Raises $5 Million in Registered Direct Offering
3. NeoStem Selected to Present at American Society for Apheresis
4. NeoStems Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference
5. NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010
6. NeoStem Announces Conversion of Convertible Preferred Stock by Principal Shareholder
7. NeoStem Provides Update on its Pharmaceutical Subsidiary Suzhou Erye
8. NeoStem, Inc. to Present at NASDAQ MarketSite
9. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
10. NeoStem Appoints Deloitte & Touche as New Independent Registered Public Accounting Firm
11. NeoStem Announces Presentation Time Change at Roth Capital Partners 22nd Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):